Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias

被引:142
作者
Monti, G
Pioltelli, P
Saccardo, F
Campanini, M
Candela, M
Cavallero, G
De Vita, S
Ferri, C
Mazzaro, C
Migliaresi, S
Ossi, E
Pietrogrande, M
Gabrielli, A
Galli, M
Invernizzi, F
机构
[1] Univ Milan, L Sacco Hosp, Inst Infect Dis & Trop Med, I-20157 Milan, Italy
[2] Saronno Hosp, Unita Operat Med Gen, Monza, Italy
[3] S Gerardo Hosp, Ist Med Interna & Ematol 2, Monza, Italy
[4] Univ Ancona, Ist Clin Med, Ancona, Italy
[5] S Croce Hosp, Unita Opert Med Gen, Cuneo, Italy
[6] Univ Udine, Ist Reumatol, I-33100 Udine, Italy
[7] Univ Pisa, Ist Patol Med & Reumatol, Pisa, Italy
[8] Univ Naples, Ist Clin Med & Reumatol, Naples, Italy
[9] Univ Padua, Ist Med Interna, Padua, Italy
[10] Univ Milan, Ist Med Interna, S Paolo Hosp, I-20122 Milan, Italy
关键词
D O I
10.1001/archinte.165.1.101
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Some patients with cryoglobulinemic syndrome (CS) develop frank non-Hodgkin lymphoma (NHL), but the incidence and timing of this event are still poorly defined. Methods: A retrospective multicenter study was performed of hepatitis C virus-positive patients with CS observed in 11 Italian centers belonging to the Italian Group for the Study of Cryoglobulinemia. Results: The inclusion criteria were satisfied by 1255 patients. During a cumulative follow-up of 8928 patient-years, 59 cases of NHL were diagnosed, for an estimated rate of 660.8 new cases per 100000 patient-years with 224.1 new cases of aggressive NHL subtypes per 100 000 patient-years. More than 90% of the patients developing NHLs had type II cryoglobulins. The NHLs were classified as nonaggressive in 31 cases (53%), aggressive in 20 (34%), and mucosa-associated lymphoid tissue lymphomas in 6 (10%); 2 cases were unclassifiable. The median time from the diagnosis of CS to the clinical onset of NHL was 6.26 years (range, 0.81-24 years). The clinical course and response to chemotherapy in the patients with CS who had NHL were similar to those usually described in patients with NHL without CS; the course of the CS only marginally benefited from chemotherapy. Conclusions: The overall risk of NHL in patients with CS is about 35 times higher than in the general population (12 times higher if nonaggressive lymphomas are excluded). The presence of CS did not significantly affect the treatment of newly diagnosed lymphomas.
引用
收藏
页码:101 / 105
页数:5
相关论文
共 26 条
  • [1] BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3
  • [2] The cryoglobulins: an overview
    Dammacco, F
    Sansonno, D
    Piccoli, C
    Tucci, FA
    Racanelli, V
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2001, 31 (07) : 628 - 638
  • [3] De Vita S, 2000, ARTHRITIS RHEUM, V43, P94, DOI 10.1002/1529-0131(200001)43:1<94::AID-ANR12>3.0.CO
  • [4] 2-8
  • [5] Characterization of overt B-cell lymphomas in patients with hepatitis C virus infection
    DeVita, S
    Sacco, C
    Sansonno, D
    Gloghini, A
    Dammacco, F
    Crovatto, M
    Santini, G
    Dolcetti, R
    Boiocchi, M
    Carbone, A
    Zagonel, V
    [J]. BLOOD, 1997, 90 (02) : 776 - 782
  • [6] HEPATITIS-C VIRUS-INFECTION IN PATIENTS WITH NON-HODGKINS-LYMPHOMA
    FERRI, C
    CARACCIOLO, F
    ZIGNEGO, AL
    LACIVITA, L
    MONTI, M
    LONGOMBARDO, G
    LOMBARDINI, F
    GRECO, F
    CAPOCHIANI, E
    MAZZONI, A
    MAZZARO, C
    PASERO, G
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1994, 88 (02) : 392 - 394
  • [7] MIXED CRYOGLOBULINEMIA - CLINICAL ASPECTS AND LONG-TERM FOLLOW-UP OF 40 PATIENTS
    GOREVIC, PD
    KASSAB, HJ
    LEVO, Y
    KOHN, R
    MELTZER, M
    PROSE, P
    FRANKLIN, EC
    [J]. AMERICAN JOURNAL OF MEDICINE, 1980, 69 (02) : 287 - 308
  • [8] SECONDARY AND ESSENTIAL CRYOGLOBULINEMIAS - FREQUENCY, NOSOLOGICAL CLASSIFICATION, AND LONG-TERM FOLLOW-UP
    INVERNIZZI, F
    GALLI, M
    SERINO, G
    MONTI, G
    MERONI, PL
    GRANATIERI, C
    ZANUSSI, C
    [J]. ACTA HAEMATOLOGICA, 1983, 70 (02) : 73 - 82
  • [9] INVERNIZZI F, 1990, IMMUNOLOGICAL ASPECT, P221
  • [10] JAFFE ES, 2001, WHO CLASSIFICATION T, V6, P47